About Leon-nanodrugs
Leon-nanodrugs is a company based in Munchen (Germany) founded in 2011 by Comelia Beier. Leon-nanodrugs has raised $20.3 million across 3 funding rounds from investors including Evotec, LBBW Venture Capital and Albany Capital. The company has 8 employees as of December 31, 2020. Leon-nanodrugs offers products and services including NANOlab, NANOme, and NANOus. Leon-nanodrugs operates in a competitive market with competitors including Sirnaomics, Arcturus Therapeutics, PharmaJet, ViAqua and Vaxxas, among others.
- Headquarter Munchen, Germany
- Employees 8 as on 31 Dec, 2020
- Founders Comelia Beier
-
Sectors
TechnologyHealthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Leon-Nanodrugs Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20.3 M (USD)
in 3 rounds
-
Latest Funding Round
Not available
-
Investors
Evotec
& 8 more
-
Employee Count
8
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Leon-nanodrugs
Leon-nanodrugs offers a comprehensive portfolio of products and services, including NANOlab, NANOme, and NANOus.
Device for fast and simplified nanoencapsulation process development.
Supports high throughput for small-scale sterile nanoencapsulation batches.
Enables scale-up for large-scale commercial GMP nanoencapsulation.
People of Leon-nanodrugs
Unlock access to complete
Funding Insights of Leon-nanodrugs
Leon-nanodrugs has successfully raised a total of $20.3M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Leon-nanodrugs
Leon-nanodrugs has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Evotec, LBBW Venture Capital and Albany Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage VC firm investing in smart & deep-tech, fin-tech and life science & health-tech sectors
|
Locked | Locked | Locked | |
|
Investments in healthtech startups are made by Albany Capital.
|
Locked | Locked | Locked | |
|
Investments are made by CD-Venture in early-stage life sciences startups.
|
Locked | Locked | Locked |
Investor details for Leon-nanodrugs
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Leon-nanodrugs
Investment portfolio details for Leon-nanodrugs
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Leon-nanodrugs
Detailed financials for Leon-nanodrugs
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Leon-Nanodrugs Comparisons
Peer comparison for Leon-nanodrugs
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Leon-nanodrugs
Leon-nanodrugs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sirnaomics, Arcturus Therapeutics, PharmaJet, ViAqua and Vaxxas, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| Locked | Locked | Locked |
RNAi technologies are developed for treating rare orphan diseases.
|
|
| Locked | Locked | Locked |
Provider of needle-free injection technology
|
|
| Locked | Locked | Locked |
RNAi drug delivery technology is developed for aquaculture disease prevention.
|
|
| Locked | Locked | Locked |
Developer of vaccines to treat cancer and infectious diseases
|
|
| Locked | Locked | Locked |
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
|
Detailed competitors of Leon-nanodrugs
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Leon-Nanodrugs
Complete news archive for Leon-nanodrugs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Leon-nanodrugs
Leon-nanodrugs was founded in 2011 and raised its 1st funding round 4 years after it was founded.
Leon-nanodrugs is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Leon-nanodrugs is a funded company, having raised a total of $20.3M across 3 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Leon-nanodrugs is 8.
Leon-nanodrugs was established in 2011 in Munich, Germany, within the biotechnology sector. Operations center on nanotechnology for drug reformulations and reinventions, utilizing MicroJetReactor technology to encapsulate substances in nanoparticles. Five internal productsIn003, In006, In008, In011, and In012are under development for oncology, metabolic, pain, and CNS applications. Offerings encompass naked nanoparticles, polymer-coated APIs, functionalized multilayered structures, surface-bound API polymers, and coated nanoemulsions, provided on contract or collaborative terms.
Leon-nanodrugs's top competitors include Sirnaomics, Arcturus Therapeutics and PharmaJet.
Leon-nanodrugs offers NANOlab, NANOme, and NANOus.
Leon-nanodrugs has 9 investors. Key investors include Evotec, LBBW Venture Capital, Albany Capital, CD-Venture, and Eckenstein-Geigy-Foundation.